SIRT1 and COVID-19: SIRT1 has an anti-inflammatory function by inhibiting ADAM17 (A Disintegrin and Metalloproteinase Domain 17), also known as TACE (TNF-α converting enzyme) as well as other pro-inflammatory agents such as TNF-α, IL-6, and IL-1b; Therefore, in a condition where SIRT1 is decreased, inflammatory activity is not inhibited and hyperinflammatory response conditions such as in COVID-19 will not be controlled [59,60,61].